Aligos Therapeutics

What Aligos Therapeutics does

Aligos Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California, with additional operations in Leuven, Belgium and Shanghai, China. The company is publicly traded on NASDAQ under the ticker ALGS and employs 51-100 people. Aligos discovers and develops novel small molecule therapies targeting liver and viral diseases, with a focused pipeline addressing chronic hepatitis B virus infection (HBV), metabolic dysfunction-associated steatohepatitis (MASH), and COVID-19.

The company's pipeline is anchored by pevifoscorvir sodium (ALG-000184), an oral capsid assembly modulator (CAM-E) currently in Phase 2 B-SUPREME development for chronic HBV with FDA Fast Track designation. ALG-055009 is an oral thyroid hormone receptor beta (THR-β) agonist in Phase 2a (HERALD study) for MASH. ALG-097558 is a ritonavir-free pan-coronavirus protease inhibitor developed in collaboration with KU Leuven and supported by NIH/NIAID contracts. ALG-170675 is a next-generation antisense oligonucleotide for HBV in nonclinical development. The underlying technology platform spans medicinal chemistry, nucleos(t)ide chemistry, and oligonucleotide chemistry, leveraging foundational IP licensed from Emory University (Dr. Schinazi laboratory) and internally developed by EVP David B. Smith.

Aligos operates as a pre-revenue clinical-stage company, generating income only through licensing and milestone payments. The April 2026 exclusive Greater China license to Xiamen Amoytop Biotech for pevifoscorvir sodium exemplifies its commercial model: $25 million upfront plus up to $420 million in milestones and tiered high single-digit royalties, with Aligos retaining rights in the US, Europe, Japan, South Korea, and other markets. Go-to-market will combine direct commercialization in retained territories (supported by the recent CCO hire) and regional licensing partnerships. The company's investors include Novo Holdings, Roche Venture Fund, Versant Ventures, Vivo Capital, Wellington Management, Boxer Capital, Cormorant, Janus Henderson, Logos Capital, and Pivotal bioVenture Partners. Total capital raised exceeds $400 million across founding, crossover, and post-IPO rounds, with cash runway extended into the second half of 2026.

Name

Aligos Therapeutics

Legal name

Aligos Therapeutics, Inc.

Website

https://aligos.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies for chronic hepatitis B, MASH, and COVID-19. Founded in 2018, it is publicly traded on NASDAQ as ALGS and operates from South San Francisco with offices in Belgium and China.

Ownership category

akta.pro rank

Product category

Antiviral and Liver Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• Hepatitis B therapeutics
• Antiviral drug development
• MASH liver therapies
• Capsid assembly modulators
• Antisense oligonucleotide drugs

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. Currently developing multiple drug candidates in Phase 1 and Phase 2 clinical trials. Revenue will be generated upon regulatory approval and commercialization of therapeutic candidates.
2. Licensing and Milestone Payments: The company receives upfront payments, clinical, regulatory, and sales milestone payments, plus royalties from licensing agreements. The Amoytop deal includes $25M upfront and up to $420M in milestones plus tiered royalties.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Aligos Therapeutics is a clinical-stage biopharmaceutical company discovering and developing novel small molecule and oligonucleotide therapeutics for liver and viral diseases. Its pipeline includes an oral capsid assembly modulator (pevifoscorvir sodium) for chronic hepatitis B, a THR-β agonist (ALG-055009) for MASH, a pan-coronavirus protease inhibitor (ALG-097558), and an antisense oligonucleotide (ALG-170675) for chronic HBV. The company monetizes these candidates through licensing deals, milestone payments, royalties, and federal research grants, with future commercial product sales following regulatory approval.

Product overview

Aligos Therapeutics is a clinical-stage biotechnology company developing a differentiated pipeline of best-in-class drug candidates for liver and viral diseases. The company's portfolio includes: pevifoscorvir sodium (ALG-000184), a capsid assembly modulator (CAM-E) for chronic hepatitis B virus infection currently in Phase 2 clinical trials; ALG-055009, a THR-β agonist for metabolic dysfunction-associated steatohepatitis (MASH) also in Phase 2; ALG-097558, a pan-coronavirus protease inhibitor for COVID-19 in Phase 2 development with NIH/NIAID funding; and ALG-170675, an antisense oligonucleotide for HBV in nonclinical/IND-enabling studies. The company leverages expertise in medicinal chemistry and biology to target liver and viral diseases with unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

• Pevifoscorvir sodium (ALG-000184) Oral small molecule capsid assembly modulator (CAM-E) designed to prevent establishment and replenishment of cccDNA levels and reduce expression of viral markers including DNA, RNA, HBsAg, HBeAg, and HBcrAg in chronic HBV infection. Demonstrated best-in-class reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg in Phase 1 studies. Licensed to Xiamen Amoytop Biotech for Greater China commercialization.
• ALG-055009 Oral small molecule thyroid hormone receptor beta (THR-β) agonist designed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH), optimized for improved potency and selectivity compared to competitor THR-β agonists.
• ALG-097558 Ritonavir-free pan-coronavirus protease inhibitor demonstrating broad pan-coronavirus activity including against SARS-CoV-2 variants, SARS, and MERS. Phase 1 studies showed acceptable PK profile without ritonavir boosting requirement.
• ALG-170675 Next-generation antisense oligonucleotide for chronic HBV infection utilizing novel monomers that reduce ASO toxicity and improve liver to kidney ratios. Operates via two mechanisms: targeting and destroying HBsAg mRNA, and activating immune response through TLR-8 agonism.
• ALG-093940 and ALG-094295 (PD-1/PD-L1 Inhibitors) Liver-targeted oral small molecule PD-1/PD-L1 inhibitors for treatment of chronic hepatitis B infection and liver cancer. Targets dimerization, internalization and degradation of PD-L1.

Quantifiable outcome

• 40% of HBeAg+ participants with chronic HBV achieved HBsAg reductions below 3,000 IU/mL at 48 weeks with pevifoscorvir sodium monotherapy
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and major.

• Xiamen Amoytop Biotech Co., Ltd. (Amoytop)coreStrategic or Co-development Partner · 16 April 2026Exclusive license agreement for development and commercialization of pevifoscorvir sodium for chronic hepatitis B in Greater China (Mainland China, Taiwan, Hong Kong, Macau). Aligos receives $25M upfront and up to $420M in clinical, regulatory, and sales milestones plus tiered high single-digit royalties. Deal extends Aligos' cash runway into Q4 2026. Aligos retains all rights in US, Europe, Japan, South Korea, and other global markets.
• Emory University (Dr. Raymond Schinazi Laboratory)coreTechnology or Integration · 1 January 2018Licensed initial IP for ALG-000184 (pevifoscorvir sodium) from Dr. Schinazi's laboratory. This foundational IP was further optimized by Aligos' medicinal chemistry team to develop the current lead compound.
• Katholieke Universiteit Leuven (KU Leuven), CISTIM, and CD3majorStrategic or Co-development Partner · 1 January 2018Collaboration for development of ALG-097558 pan-coronavirus protease inhibitor. KU Leuven, Center for Innovation and Stimulation of Drug Discovery (CISTIM), and Centre for Drug Design and Discovery (CD3) contributed to discovery and development of the compound. ALG-097558 has shown at least 6-fold greater potency than nirmatrelvir against SARS-CoV-2 variants.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arbutus Biopharma: Clinical-stage HBV company developing capsid inhibitors, RNAi agents (AB-729), and oral PD-L1 inhibitors. Most directly comparable to Aligos in HBV modality mix and target patient population, with overlapping mechanisms on capsid and PD-L1.
• Assembly Biosciences: Clinical-stage HBV company developing capsid assembly modulators (vebicorvir) and other HBV mechanisms. Directly competes in the same HBV CAM space as pevifoscorvir sodium with similar small-molecule approach to functional cure.
• Vir Biotechnology: Clinical-stage infectious disease company with HBV combination regimens (VIR-2218 siRNA plus VIR-3434 monoclonal antibody) plus COVID and influenza programs. Comparable multi-asset virology pipeline targeting the same HBV functional cure opportunity.
• Brii Biosciences: China-based HBV-focused biotech with topline data from Phase 2 trials and active China commercialization. Comparable HBV pipeline focus and Asia-Pacific market presence, relevant given Aligos' Amoytop partnership for Greater China.
• Madrigal Pharmaceuticals: Developer of Rezdiffra (resmetirom), the first FDA-approved THR-β agonist for MASH. Most direct competitor to ALG-055009 in the THR-β MASH space and a benchmark for Aligos' commercial pathway and clinical positioning.
• Terns Pharmaceuticals: Clinical-stage biotech developing TERN-701 (allosteric BCR-ABL inhibitor for CML) plus HBV and MASH programs. Comparable small-molecule approach to liver and viral diseases with similar pipeline breadth.
• Akero Therapeutics: Clinical-stage MASH company developing efruxifermin (FGF21 analog) in Phase 3. Comparable MASH pipeline asset and similar small-cap clinical-stage positioning targeting the same liver disease opportunity as ALG-055009.

Broad incumbents

• Gilead Sciences: Large biopharmaceutical company with major HBV franchise (Vemlidy, Viread), HCV leadership, and siRNA-based HBV programs through partnerships. Broad incumbent with overlapping HBV interest and significantly greater resources.
• Roche: Large biopharmaceutical company with HBV assets (RG6346 siRNA) and historical investment via Roche Venture Fund in Aligos. Broad incumbent in virology with deeper R&D capacity in oligonucleotide-based HBV therapeutics.
• Pfizer: Developer of PAXLOVID (nirmatrelvir/ritonavir) for COVID-19 and acquirer of Seagen for oncology. Broad incumbent competing with ALG-097558 in the COVID antiviral space and in MASH through internal programs and partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aligos-therapeutics
• Xx.com/Aligos7
• Facebookfacebook.com/aligos.therapeutic

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aligos Therapeutics